Brief: Oasmia’s Partner Elevar Provides Update On Apealea Development Plans In Ovarian Cancer

Vivesto AB

03/12/2020 12:09

Dec 3 (Reuters) - Oasmia Pharmaceutical AB  OASM.ST :
    * OASMIA’S PARTNER ELEVAR PROVIDES AN UPDATE ON APEALEA
DEVELOPMENT PLANS IN OVARIAN CANCER
    * ELEVAR TO COMPLETE TWO NEW STUDIES WITH APEALEA, WHICH
WILL BOTH
BE INITIATED IN FIRST HALF OF 2021
    * FIRST STUDY PLANNED BY ELEVAR IS A PHARMACOKINETICS STUDY,
WHICH
ELEVAR AIMS TO INITIATE IN FIRST HALF OF 2021.
    * ELEVAR TO INITIATE A PIVOTAL SUPERIORITY STUDY TO
INVESTIGATE
SAFETY AND EFFICACY OF APEALEA IN EPITHELIAL OVARIAN CANCER.

Source text for Eikon:  ID:nMFN7xLkqm 
Further company coverage:  OASM.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))